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Abstract
Background: Brain metastases develop in approximately 
10–25% of patients with metastatic breast cancer (MBC) and 
are associated with a very poor prognosis. Case Report: We 
report the case of a 40-year-old woman with MBC and asso-
ciated lung, bone, liver, and brain metastases, who experi-
enced a time to progression of several months with eribulin 
after whole-brain radiotherapy (WBRT), 2 lines of chemo-
therapy, and 1 line of hormonal therapy, maintaining a good 
toxicity profile. Discussion: Eribulin, in association with local 
treatment such as WBRT, can be well tolerated and effective 
in achieving a long progression-free survival and a good 
control of brain metastases in patients with MBC who have 
received multiple lines of treatment. The vascular remodel-
ing properties of eribulin, combined with brain radiothera-
py, might facilitate the passage of eribulin across the blood 
brain barrier, improving brain response. Conclusion: Our an-
ecdotal experience suggests that eribulin may have a poten-
tially beneficial effect on brain metastases while maintaining 
a good systemic control of the disease in patients with MBC.
© 2018 The Author(s) 
Published by S. Karger AG, Basel
Background
Breast cancer (BC) is the most common malignant dis-
order in women. Although treatable, metastatic BC 
(MBC) remains an incurable disease with a median over-
all survival (OS) of 2–3 years and a 5-year survival of only 
25% [1–3]. In the last decade, slow progress has been 
made in terms of improved outcomes, quality of life, 
awareness, and information regarding the biology and 
heterogeneity of BC [4].
There is no standard regimen for patients with MBC 
who recur after treatment with an anthracycline and a 
taxane, both in the adjuvant and metastatic setting, and 
who are not eligible for combination chemotherapy or 
endocrine therapy. In this setting of patients, single 
agent capecitabine, eribulin, vinorelbine, gemcitabine, 
platinum agents, taxanes, or liposomal anthracyclines 
are the preferred options. Treatment choice should be 
individualized and take into account different toxicity 
profiles, previous treatments, and also patient’s prefer-
ences [5].
Eribulin mesylate (eribulin) is a microtubule dynamics 
inhibitor approved by the European Medicines Agency 
(EMA) in March 2011 for the treatment of MBC in pa-
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tients who had received 2 or more prior chemotherapy 
regimens for their disease. 
This approval was based on results from the EM-
BRACE study, a phase III, open-label, randomized clini-
cal trial, in which eribulin was compared with treatment 
of physician’s choice (TPC) in patients with locally recur-
rent or metastatic BC who had received 2–5 prior chemo-
therapeutic regimens (including an anthracycline and a 
taxane for early or advanced disease), with ≥2 chemo-
therapies for advanced disease [6]. In this study, the me-
dian OS was significantly longer with eribulin than with 
TPC (hazard ratio [HR] 0.81; 95% confidence interval 
[CI] 0.67–0.96; p = 0.014]. There was also a significant 
difference in favor of eribulin in progression-free surviv-
al (PFS), as assessed by the investigators (HR 0.76; 95% CI 
0.64–0.90; p = 0.002), but not by independent reviewers 
(HR 0.87; 95% CI 0.71–1.05; p = 0.137). Frequent toxici-
ties included neutropenia (52% with eribulin vs. 30% with 
TPC), fatigue (54 vs. 40%), nausea (35 vs. 28%), and pe-
ripheral neuropathy (35 vs. 16%).
Support for this indication also came from Study 301, 
which compared eribulin and capecitabine as first-, sec-
ond-, or third-line therapy in women with locally ad-
vanced or metastatic BC who had previously received an 
anthracycline and a taxane. In this study, a significant 
survival benefit for eribulin over capecitabine was not 
demonstrated in the overall population (HR 0.88; 95% CI 
0.77–1.00; p = 0.056); however, prespecified subgroup 
analyses showed a longer OS for eribulin compared with 
capecitabine in patients with human epidermal growth 
factor receptor 2 (HER2)-negative disease or triple-nega-
tive BC [7]. 
A pooled analysis of these two phase III trials reported 
an overall OS benefit of 2.4 months with eribulin com-
pared to control therapy (HR 0.85; 95% CI 0.77–0.95; p = 
0.003) and an overall PFS benefit of 0.6 months (HR 0.90; 
95% CI 0.81–0.997; p = 0.046) [8]. All analyzed patient’s 
subgroups favored treatment with eribulin compared to 
control, with particular OS benefit observed in patients 
with HER2-negative disease (HR 0.82; 95% CI 0.72–0.93; 
p = 0.002), triple-negative BC (HR 0.74; 95% CI 0.60–
0.92; p = 0.006), and patients with > 2 affected organs (HR 
0.77; 95% CI 0.66–0.89; p < 0.001). Several previously 
published case reports and other real-life clinical experi-
ences have shown the efficacy of treatment with eribulin 
in highly pretreated patients with MBC and have also 
shown its good manageability and good toxicity profile 
[9]. In 2015, a case report of an MBC patient who achieved 
a very long time to progression (23 months) with eribulin 
was reported [10].
Brain metastases develop in approximately 10–25% of 
patients with MBC and are associated with worst progno-
sis [11, 12]. Whole-brain radiotherapy (WBRT) or stereo-
tactic radiation therapy (depending on the number and 
sites of brain metastasis) is considered the standard treat-
ment for brain metastasis [13, 14]. This case report de-
scribes a patient with MBC and brain metastases who ex-
perienced a time to progression of several months with 
eribulin after brain radiotherapy, 2 lines of chemotherapy 
and 1 line of hormonal therapy, maintaining a good tox-
icity profile.
Case Report
In July 2013, a 40-year-old woman underwent breast conserv-
ing surgery and was diagnosed with a moderately differentiated 
(G2) infiltrating ductal carcinoma of the right breast (estrogen re-
ceptor [ER] 90%, progesterone receptor [PgR] 60%, HER2–, Ki67 
10%), at the pT1bpN0 M0 stage.
Based on the disease stage and prognostic factors, adjuvant 
hormonal therapy with tamoxifen was administered starting from 
August 2013. Between August and September 2013, she also re-
ceived 25 radiotherapy sessions (50 Gy). In February 2015, after 18 
months of disease-free survival, a CT scan and PET showed bilat-
eral lung metastatic lesions.
In March 2015, she underwent atypical resection of the right 
lung. Pathological evaluation revealed lung metastasis of adeno-
carcinoma sharing immunophenotypic features with ductal carci-
noma of the breast (ER 90%, PgR 15%, HER2–, Ki67 30%). 
In April 2015, the patient started a first-line chemotherapy with 
nab-paclitaxel (125 mg/m2; days 1, 8, and 15 of a 21-day cycle) and 
nonpegylated liposomal doxorubicin (20 mg/m2; days 1, 8, and 15 
of a 21-day cycle) for 4 cycles and achieved a partial response of 
disease. In September 2015, a CT scan after 7 cycles of chemother-
apy confirmed a partial response of disease. In January 2016, a CT 
scan after 10 cycles of chemotherapy showed a further partial re-
sponse. Given the good response observed, in February 2016 che-
motherapy was discontinued after 10 cycles, and the patient start-
ed hormonotherapy with fulvestrant (500 mg; days 1 and 14 of a 
28-day cycle) as maintenance treatment.
In May 2016 and in October 2016, CT scans showed a stable 
disease after 4 cycles and 10 cycles of fulvestrant as maintenance, 
respectively. In January 2017, after a PFS of 21 months, scintigra-
phy scan, CT scan, and MRI showed a systemic progressive disease 
including increased lung metastasis, appearance of bone metasta-
sis (right acetabulum, sacrum, iliac spine, left rib, and D9 vertebral 
body) and brain metastasis (right angular gyrus 7 mm; left occipi-
tal region 7 and 5 mm). There were no neurological symptoms. 
Because of progressive disease, fulvestrant was discontinued, 
the patient received WBRT (total 30 Gy), and oral steroid was ad-
ministered. After WBRT, in February 2017 she started second-line 
chemotherapy with capecitabine (2,000 mg/m2 die, per os on days 
1–14, with a 1-week withdrawal period, every 3 weeks). In April 
2017, she also started treatment with denosumab (120 mg every 4 
weeks). In July 2017, a CT scan, after 6 cycles of capecitabine, 
showed partial response of brain metastasis but also disease pro-
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gression in bone (C5–D2 and D9–D11 vertebral body) and lung, 
and appearance of liver metastasis (target lesions: II segment 
8 mm; IV segment 10 mm; I–III segment 30 + 27 mm). Due to the 
high risk of fracture, the patient received vertebral radiotherapy. 
In August 2017, after a PFS of 6 months, she started third-line che-
motherapy with eribulin at a dosage of 1.23 mg/m2 on days 1 and 
8 every 21 days. We decided to use granulocyte colony-stimulating 
factor prophylaxis because of previous treatments, and the patient 
continued denosumab therapy at the same schedule. 
In November 2017, MRI showed stable disease according to the 
RANO criteria for brain with the presence of two metastases 
(Fig. 1a, b), while a CT scan showed stability in bone metastasis 
and partial response in liver metastasis (target lesions: II segment 
5 mm; IV segment 10 mm; I–III segment 23 + 20 mm). The treat-
ment was well tolerated, and the patient experienced G1–G2 ane-
mia, alopecia, and moderate fatigue. 
Given the partial remission in extracranial disease, eribulin 
treatment was administered for 3 more cycles. In January 2018, 
MRI showed a reduction of the dimensions of both brain lesions 
(right angular gyrus 2 mm; left occipital region 2 mm) (Fig. 1c, d), 
while metastases on the left occipital area were stable. CT scan 
documented no change of bone metastasis and a further decrease 
in the volume of liver metastasis (target lesions: II segment 5 mm; 
IV segment 8 mm; I–III segment 17 mm). 
Based on further partial remission reported by the patient, the 
treatment has been continued and it is still ongoing. Until now, no 
serious adverse event was reported during eribulin treatment and 
no treatment cycle was delayed for hematological toxicity. More-
over, until now, we obtained a PFS of 6 months, which is greater 
than median PFS resulting from the EMBRACE study [6]. Of 
course, this represents a great success in a patient with brain me-
tastasis and in the third line of treatment. 
Discussion
In our case report, a patient affected by MBC showed 
sustained disease control, lasting 12 months after the ap-
pearance of brain metastasis and still ongoing thanks to a 
combination of multiple therapies that included WBRT 
and chemotherapy. In particular, WBRT followed by er-
ibulin led to a continuous control of brain metastasis, 
with systemic disease stability for 6 months until now. 
The prognosis associated with brain metastasis is very 
poor. Chemotherapeutic agents do not easily cross the 
blood-brain barrier, while radiation therapy is known to 
compromise the barrier function [15] by reducing the ex-
pression of the efflux transporter P-glycoprotein [16]. Evi-
dence suggests that this effect may last for as long as several 
years after postradiation therapy [15]. A number of case 
reports and other small studies have demonstrated that pa-
tients with brain metastasis arising from HER2-negative BC 
may benefit from capecitabine treatment [17, 18].
In our case report, treatment with WBRT and subse-
quent capecitabine chemotherapy led to a good response 
on brain metastasis that was maintained even when sys-
temic disease progression was evident. Subsequent treat-
ment with eribulin has shown a sustained control of brain 
disease, lasting over 6 months after the end of WBRT, and 
also a continuous partial response of visceral disease, es-
pecially in the liver.
Patients with brain metastasis are poorly represented 
in the EMBRACE study; indeed presence of brain metas-
tases often leads to exclusion from clinical trials. How-
ever, there have been a number of reports describing re-
sponse to eribulin in BC patients with brain metastases.
In 2013, a case report showed the efficacy of eribulin 
in a 57-year-old woman with brain metastases arising 
from BC [19]. This patient received radiotherapy for 
brain metastases and then treatment with lapatinib and 
capecitabine. After 3 months, she experienced progres-
a b
c d
Fig. 1. MR T1 sequences in axial planes after contrast medium in-
fusion. a, b Pre-treatment MR shows two lesions (black arrows) in 
the right angular gyrus and in the left occipital lobe, with vaso-
genic edema. c, d MR after 6 cycles of eribulin shows a reduction 
of the dimension of the lesions (white arrow) in relation to re-
sponse to treatment.
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sion of brain and liver metastases and was treated with 
eribulin. After 1 month, brain lesions decreased signifi-
cantly in size, and this decrease was maintained for at 
least 4 months.
Eribulin does not cross the healthy blood-brain bar-
rier, but could have the potential to do so after WBRT 
[20]. Indeed, brain radiotherapy may have facilitated er-
ibulin passage across the blood-brain barrier in our pa-
tient, by decreasing the activity of P-glycoprotein. The 
antiangiogenic action of eribulin could have also contrib-
uted to this process. In fact, data on eribulin’s antivascular 
activity have already been reported, showing how eribu-
lin can influence the remodeling of tumor vasculature 
[21, 22].
In our opinion, although this is only an anecdotal ex-
perience, eribulin proved to be a well-tolerated active 
monotherapy after previous regimens. Eribulin ensured 
a clinically significant survival improvement, with con-
trol of brain metastases, reduction of visceral metastasis 
and clinical benefit.
With the limits of its anecdotal nature, this experience 
also confirms the positive results obtained with eribulin 
in brain metastasis, as reported in other previously pub-
lished case reports.
The benefit observed with eribulin after multiple lines 
of therapy also suggests that an earlier introduction of this 
agent might have been associated with a longer disease 
control compared with other drugs used in this patient.
In our experience, eribulin treatment was associated 
with a good toxicity profile, and patient’s quality of life 
was preserved. The standard schedule of eribulin was ad-
ministered without any difficulties; thanks to the support 
of granulocyte colony-stimulating factor, the patient did 
not suffer from neutropenia or febrile neutropenia, and 
peripheral neuropathy was not reported. These results 
suggest that eribulin, in association with local treatments 
such as radiotherapy, can be well tolerated and effective 
in achieving a long PFS and a good control of brain me-
tastasis in patients with MBC who have received multiple 
lines of treatment.
Conclusion
Our anecdotal experience suggests that eribulin may 
have a potentially beneficial effect on brain metastases 
while maintaining a good systemic control of the disease 
in patients with MBC. Future studies are warranted to 
evaluate the activity of eribulin and its mechanism of ac-
tion in BC-associated central nervous system metastases.
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